Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04030091 · ClinicalTrials.gov registry record · Phase 4
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
A Phase 4 study, sponsored by Sciema UG.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT04030091 is a Phase 4 study that has completed, run by Sciema UG. The registered enrollment target is 24 participants.
The verdict
NCT04030091, a Phase 4 study, has completed, sponsored by Sciema UG.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study is an open label, prospective, randomised comparative, single center study. In the present study, the impact of a 12-week pulsatile insulin infusion therapy (PIT) with Humulin R 100 from
Interventions
- DRUG 3 hours humulin R 100 IU/mL PIT
- DRUG 2 hours humulin R 100 IU/mL PIT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-09-06 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04030091
The ClinicalTrials.gov registry entry for NCT04030091 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sciema UG, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 3 hours humulin R 100 IU/mL PIT is the first listed.
NCT04030091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04030091 about?
NCT04030091 is a clinical study titled "Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus". This study is an open label, prospective, randomised comparative, single center study. In the present study, the impact of a 12-week pulsatile insulin infusion therapy (PIT) with Humulin R 100 from
What is the current status of trial NCT04030091?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2019-09-06. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT04030091?
The interventions under investigation include: 3 hours humulin R 100 IU/mL PIT (DRUG), 2 hours humulin R 100 IU/mL PIT (DRUG).
Who is sponsoring clinical trial NCT04030091?
This trial is sponsored by Sciema UG, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.